Bristol-Myers Squibb (BMY) Tops Q3 EPS by 20c; Raises Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Bristol-Myers Squibb (BMY) Tops Q3 EPS by 20c; Raises Outlook

Bristol-Myers Squibb Reports Third Quarter Financial Results

October 25, 2018 6:59 AM EDT

Increases Third Quarter Revenues 8% to $5.7 Billion Posts Third Quarter GAAP EPS of $1.16 and Non-GAAP EPS of $1.09 Presents Important New Clinical Data on Novel, Oral, Selective TYK2 Inhibitor for Potential Treatment of Patients with Moderate to Severe Plaque Psoriasis Additional Opdivo Approvals Including for Adjuvant Treatment of Adult Patients with Melanoma in the European Union Updates on Ongoing Regulatory Review of Opdivo Plus Low-Dose Yervoy in First-Line Lung Cancer Updates... More